In the United States, public health advocates are raising concerns about the Food and Drug Administration’s approval of the first prescription drug to increase women’s sexual desire. Flibanserin is made by Sprout Pharmaceuticals, whose executives have previously run afoul of the FDA for their misleading and inaccurate marketing of an earlier product. The medication’s approval was aggressively pushed by an advocacy group called Even the Score, which was funded by the drugmaker and other pharmaceutical companies. Some health advocates have raised concerns about potentially serious risks, including low blood pressure and fainting. In a statement, Dr. Sidney Wolfe of Public Citizen said, “Unfortunately, we haven’t heard the last of this drug. Expect future news to include stories of women who are harmed needlessly by flibanserin and the eventual agency call for the manufacturer to pull it from pharmacy shelves.”